• Je něco špatně v tomto záznamu ?

Hypoxia-inducible factors: master regulators of hypoxic tumor immune escape

Q. Wu, L. You, E. Nepovimova, Z. Heger, W. Wu, K. Kuca, V. Adam

. 2022 ; 15 (1) : 77. [pub] 20220603

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc22018061

Grantová podpora
31972741 Natural Science Foundation of Jilin Province
2016T90477 Postdoctoral Science Foundation of Jiangsu Province
759585 H2020 European Research Council

Hypoxia, a common feature of the tumor microenvironment in various types of cancers, weakens cytotoxic T cell function and causes recruitment of regulatory T cells, thereby reducing tumoral immunogenicity. Studies have demonstrated that hypoxia and hypoxia-inducible factors (HIFs) 1 and 2 alpha (HIF1A and HIF2A) are involved in tumor immune escape. Under hypoxia, activation of HIF1A induces a series of signaling events, including through programmed death receptor-1/programmed death ligand-1. Moreover, hypoxia triggers shedding of complex class I chain-associated molecules through nitric oxide signaling impairment to disrupt immune surveillance by natural killer cells. The HIF-1-galactose-3-O-sulfotransferase 1-sulfatide axis enhances tumor immune escape via increased tumor cell-platelet binding. HIF2A upregulates stem cell factor expression to recruit tumor-infiltrating mast cells and increase levels of cytokines interleukin-10 and transforming growth factor-β, resulting in an immunosuppressive tumor microenvironment. Additionally, HIF1A upregulates expression of tumor-associated long noncoding RNAs and suppresses immune cell function, enabling tumor immune escape. Overall, elucidating the underlying mechanisms by which HIFs promote evasion of tumor immune surveillance will allow for targeting HIF in tumor treatment. This review discusses the current knowledge of how hypoxia and HIFs facilitate tumor immune escape, with evidence to date implicating HIF1A as a molecular target in such immune escape. This review provides further insight into the mechanism of tumor immune escape, and strategies for tumor immunotherapy are suggested.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22018061
003      
CZ-PrNML
005      
20220804134531.0
007      
ta
008      
220720s2022 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s13045-022-01292-6 $2 doi
035    __
$a (PubMed)35659268
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Wu, Qinghua $u College of Life Science, Yangtze University, Jingzhou, 434025, China $u Department of Chemistry, Faculty of Science, University of Hradec Kralove, 50003, Hradec Kralove, Czech Republic
245    10
$a Hypoxia-inducible factors: master regulators of hypoxic tumor immune escape / $c Q. Wu, L. You, E. Nepovimova, Z. Heger, W. Wu, K. Kuca, V. Adam
520    9_
$a Hypoxia, a common feature of the tumor microenvironment in various types of cancers, weakens cytotoxic T cell function and causes recruitment of regulatory T cells, thereby reducing tumoral immunogenicity. Studies have demonstrated that hypoxia and hypoxia-inducible factors (HIFs) 1 and 2 alpha (HIF1A and HIF2A) are involved in tumor immune escape. Under hypoxia, activation of HIF1A induces a series of signaling events, including through programmed death receptor-1/programmed death ligand-1. Moreover, hypoxia triggers shedding of complex class I chain-associated molecules through nitric oxide signaling impairment to disrupt immune surveillance by natural killer cells. The HIF-1-galactose-3-O-sulfotransferase 1-sulfatide axis enhances tumor immune escape via increased tumor cell-platelet binding. HIF2A upregulates stem cell factor expression to recruit tumor-infiltrating mast cells and increase levels of cytokines interleukin-10 and transforming growth factor-β, resulting in an immunosuppressive tumor microenvironment. Additionally, HIF1A upregulates expression of tumor-associated long noncoding RNAs and suppresses immune cell function, enabling tumor immune escape. Overall, elucidating the underlying mechanisms by which HIFs promote evasion of tumor immune surveillance will allow for targeting HIF in tumor treatment. This review discusses the current knowledge of how hypoxia and HIFs facilitate tumor immune escape, with evidence to date implicating HIF1A as a molecular target in such immune escape. This review provides further insight into the mechanism of tumor immune escape, and strategies for tumor immunotherapy are suggested.
650    _2
$a lidé $7 D006801
650    _2
$a hypoxie $x metabolismus $7 D000860
650    _2
$a faktor 1 indukovatelný hypoxií - podjednotka alfa $7 D051795
650    _2
$a imunitní dozor $7 D007157
650    12
$a nádory $7 D009369
650    12
$a únik nádoru z imunitní kontroly $7 D019139
650    _2
$a nádorové mikroprostředí $7 D059016
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a You, Li $u College of Life Science, Yangtze University, Jingzhou, 434025, China
700    1_
$a Nepovimova, Eugenie $u Department of Chemistry, Faculty of Science, University of Hradec Kralove, 50003, Hradec Kralove, Czech Republic
700    1_
$a Heger, Zbynek $u Department of Chemistry and Biochemistry, Mendel University in Brno, Brno, 613 00, Czech Republic $u Central European Institute of Technology, Brno University of Technology, Brno, 602 00, Czech Republic
700    1_
$a Wu, Wenda $u MOE Joint International Research Laboratory of Animal Health and Food Safety, College of Veterinary Medicine, Nanjing Agricultural University, Nanjing, 210095, China. wuwenda@njau.edu.cn $u Department of Chemistry, Faculty of Science, University of Hradec Kralove, 50003, Hradec Kralove, Czech Republic. wuwenda@njau.edu.cn
700    1_
$a Kuca, Kamil $u Department of Chemistry, Faculty of Science, University of Hradec Kralove, 50003, Hradec Kralove, Czech Republic. kamil.kuca@uhk.cz
700    1_
$a Adam, Vojtech $u Department of Chemistry and Biochemistry, Mendel University in Brno, Brno, 613 00, Czech Republic. vojtech.adam@mendelu.cz $u Central European Institute of Technology, Brno University of Technology, Brno, 602 00, Czech Republic. vojtech.adam@mendelu.cz $1 https://orcid.org/000000028527286X $7 xx0064599
773    0_
$w MED00165458 $t Journal of hematology & oncology $x 1756-8722 $g Roč. 15, č. 1 (2022), s. 77
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35659268 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804134525 $b ABA008
999    __
$a ok $b bmc $g 1821905 $s 1169304
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 15 $c 1 $d 77 $e 20220603 $i 1756-8722 $m Journal of hematology & oncology $n J Hematol Oncol $x MED00165458
GRA    __
$a 31972741 $p Natural Science Foundation of Jilin Province
GRA    __
$a 2016T90477 $p Postdoctoral Science Foundation of Jiangsu Province
GRA    __
$a 759585 $p H2020 European Research Council
LZP    __
$a Pubmed-20220720

Najít záznam

Citační ukazatele

Nahrávání dat ...

    Možnosti archivace